| 宋锦辉,刘燊仡,赖楚儿,靳雁岚,王义军.如意珍宝丸联合中药治疗急性痛风性关节炎临床疗效的回顾性分析[J].现代生物医学进展英文版,2022,(20):3941-3945. |
| 如意珍宝丸联合中药治疗急性痛风性关节炎临床疗效的回顾性分析 |
| A Retrospective Analysis of Clinical Efficacy of Ruyi Zhenbao Pill Combined with Traditional Chinese Medicine in the Treatment of Acute Gouty Arthritis |
| Received:April 01, 2022 Revised:April 25, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.20.028 |
| 中文关键词: 痛风性关节炎 如意珍宝丸 中医药 回顾性研究 |
| 英文关键词: Gouty arthritis Ru Yi Zhen Bao Wan Chinese medicine Retrospective study |
| 基金项目:中国中医科学院科技创新工程（CI2021A01504） |
|
| Hits: 689 |
| Download times: 564 |
| 中文摘要: |
| 摘要 目的：回顾性分析如意珍宝丸联合中药治疗急性痛风性关节炎的临床疗效，探讨其治疗效果。方法：回顾性分析2021年6月至2021年12月就诊于中国中医科学院望京医院门诊的120例急性痛风性关节炎患者的临床资料，按照治疗方案不同分观察组和对照组，两组各60例。对照组使用非甾体抗炎药治疗，观察组在对照组基础上联合使用中药加如意珍宝丸治疗，疗程为7天。比较分析两组患者治疗后总有效率，关节疼痛VAS评分，血尿酸、C反应蛋白等实验室指标，不良反应发生率及安全性指标。结果：观察组有效率为：91.7%（55/60），高于对照组：75%（45/60）（P<0.05）。治疗后，观察组患者关节疼痛视觉模拟评分、血尿酸（UA）、C反应蛋白（CRP）低于对照组，差异具有统计学意义（P<0.05）；不良反应发生率观察组（5%）较对照组（15%）低；两组患者治疗后安全性指标无统计学差异（P＞0.05）。结论：如意珍宝丸联合中药可以有效治疗急性期痛风性关节炎，缓解患者临床症状，降低血尿酸、CRP等实验室指标，不良反应发生率低，具有一定的临床价值。 |
| 英文摘要: |
| ABSTRACT Objective: To retrospectively analyze the clinical efficacy of Ruyi Zhenbao Pill combined with traditional Chinese medicine on acute gouty arthritis and explore its therapeutic effect. Methods: The clinical data of 120 patients with acute gouty arthritis who visited Wangjing Hospital of the Chinese Academy of Traditional Chinese Medicine from June 2021 to December 2021 were retrospectively analyzed, and 60 cases in each of the two groups were divided into observation and control groups according to different treatment regimens. The control group was treated with non-steroidal anti-inflammatory drugs, while the observation group was treated with traditional Chinese medicine plus Ruyi Zhenbao Pill on the basis of the control group. The efficacy, VAS score of joint pain, laboratory indexes such as blood uric acid and C-reactive protein, incidence of adverse reactions and safety indexes of the two groups were compared and analyzed. Results: The effective rate of the observation group was: 91.7% (55/60), which was higher than that of the control group: 75% (45/60) (P<0.05). After treatment, the visual analogue score of joint pain, blood uric acid (UA) and C-reactive protein (CRP) were lower in the observation group than in the control group, and the difference was statistically significant (P<0.05); the incidence of adverse reactions was lower in the observation group (5%) than in the control group (15%); there was no statistical difference between the safety indexes of the two groups after treatment (P>0.05). Conclusion: Ruyi Zhenbao pill combined with traditional Chinese medicine can effectively treat acute stage gouty arthritis, relieve patients' clinical symptoms, reduce blood uric acid, CRP and other laboratory indicators, and have a low incidence of adverse reactions, which has certain clinical value. |
|
View Full Text
View/Add Comment Download reader |
| Close |
